title: Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties.
abstract: Predicting the response of a specific cancer to a therapy is a major goal in modern oncology that should ultimately lead to a personalised treatment. High-throughput screenings of potentially active compounds against a panel of genomically heterogeneous cancer cell lines have unveiled multiple relationships between genomic alterations and drug responses. Various computational approaches have been proposed to predict sensitivity based on genomic features, while others have used the chemical properties of the drugs to ascertain their effect. In an effort to integrate these complementary approaches, we developed machine learning models to predict the response of cancer cell lines to drug treatment, quantified through IC₅₀ values, based on both the genomic features of the cell lines and the chemical properties of the considered drugs. Models predicted IC₅₀ values in a 8-fold cross-validation and an independent blind test with coefficient of determination R² of 0.72 and 0.64 respectively. Furthermore, models were able to predict with comparable accuracy (R² of 0.61) IC50s of cell lines from a tissue not used in the training stage. Our in silico models can be used to optimise the experimental design of drug-cell screenings by estimating a large proportion of missing IC₅₀ values rather than experimentally measuring them. The implications of our results go beyond virtual drug screening design: potentially thousands of drugs could be probed in silico to systematically test their potential efficacy as anti-tumour agents based on their structure, thus providing a computational framework to identify new drug repositioning opportunities as well as ultimately be useful for personalized medicine by linking the genomic traits of patients to drug sensitivity.
authors: European Bioinformatics Institute, Wellcome Trust Genome Campus-Cambridge, Cambridge, United Kingdom.
authors: Michael P
authors: MP
authors: Menden
authors: Francesco
authors: F
authors: Iorio
authors: Mathew
authors: M
authors: Garnett
authors: Ultan
authors: U
authors: McDermott
authors: Cyril H
authors: CH
authors: Benes
authors: Pedro J
authors: PJ
authors: Ballester
authors: Julio
authors: J
authors: Saez-Rodriguez
mesh_terms: D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001185:Artificial Intelligence; D003198:Computer Simulation; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D023281:Genomics / Q000379:methods; D006801:Humans; D020128:Inhibitory Concentration 50; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics*; D010597:Pharmacogenetics / Q000379:methods; D057188:Workflow
chemical_list: D000970:Antineoplastic Agents
references: Genome Biol. 2007;8(5):R77
references: 17498287
references: PLoS One. 2009 Sep 04;4(9):e6907
references: 19730698
references: Nat Rev Drug Discov. 2012 Feb 10;11(3):201-14
references: 22322254
references: Mol Syst Biol. 2009;5:310
references: 19888205
references: Pharmacogenomics J. 2012 Oct;12(5):446-52
references: 21826086
references: J Comput Biol. 2012 Feb;19(2):163-74
references: 22300318
references: Mol Syst Biol. 2008;4:169
references: 18277385
references: J Cancer Res Clin Oncol. 1990;116(6):529-37
references: 2254371
references: Semin Oncol. 1992 Dec;19(6):622-38
references: 1462164
references: Curr Opin Genet Dev. 2010 Feb;20(1):15-22
references: 20096559
references: J Chem Inf Comput Sci. 1998 Mar-Apr;38(2):189-99
references: 9538518
references: Nat Rev Cancer. 2010 Apr;10(4):241-53
references: 20300105
references: J Natl Cancer Inst. 1989 Jul 19;81(14):1088-92
references: 2738938
references: J Mol Graph Model. 2002 Jan;20(4):297-303
references: 11858638
references: Bioinformatics. 2005 Jun;21 Suppl 1:i359-68
references: 15961479
references: J Chem Inf Model. 2010 May 24;50(5):716-31
references: 20387860
references: Nat Rev Drug Discov. 2004 Aug;3(8):673-83
references: 15286734
references: Nature. 2006 Jan 19;439(7074):358-62
references: 16273091
references: Nature. 2012 Mar 28;483(7391):603-7
references: 22460905
references: PLoS Comput Biol. 2011 Mar;7(3):e1001095
references: 21390271
references: Nat Med. 2011 Mar;17(3):330-9
references: 21386836
references: PLoS One. 2010 Oct 19;5(10):e13367
references: 20976054
references: Cancer Res. 2012 Jul 15;72(14):3499-511
references: 22802077
references: Nature. 2012 Mar 28;483(7391):570-5
references: 22460902
references: J Comput Chem. 2011 May;32(7):1466-74
references: 21425294
references: Bioinformatics. 2012 Dec 15;28(24):3334-5
references: 23080119
references: J Chem Inf Comput Sci. 2000 Mar-Apr;40(2):367-79
references: 10761142
references: Drug Discov Today. 2013 Apr;18(7-8):350-7
references: 22897878
references: Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2724-9
references: 22003129
references: Mol Cancer Ther. 2010 Feb;9(2):257-67
references: 20124458
references: Brief Bioinform. 2011 Jul;12(4):301-2
references: 21768130
references: Science. 2006 Sep 29;313(5795):1929-35
references: 17008526
references: Nat Biotechnol. 2008 May;26(5):531-9
references: 18464786